Skip to content
March 29, 2024

Equity.Guru

Investment information for the new generation

Search

Amerimmune

Histogen (HSTO.Q), and its partner Amerimmune, today announced top-line results from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy….